Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder
Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of a fixed dose of SR58611A(350 mg q12) compared to placebo in
patients with MajorDepressive Disorder (MDD) using escitalopram (10 mgqd) as positive
control. In addition, the tolerability and safety of SR58611A in patients with MDD will be
evaluated.